Abacavir/dolutegravir/lamivudine/cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamideRenal toxicity: 2 case reports

被引：0
作者：
机构：
来源：
Reactions Weekly | 2025年 / 2048卷 / 1期
关键词：
D O I：
10.1007/s40278-025-78234-8
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：14 / 14
相关论文
共 50 条
  • [41] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
    Devred, Ines
    Kayembe, Kick
    Valin, Nadia
    Rougier, Hayette
    Shinga, Bruce Wuembulua
    Lambert-Niclot, Sidonie
    Chiarabini, Thibault
    Meyohas, Marie-Caroline
    Lacombe, Karine
    [J]. BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [42] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
    Inès Devred
    Kick Kayembe
    Nadia Valin
    Hayette Rougier
    Bruce Wuembulua Shinga
    Sidonie Lambert-Niclot
    Thibault Chiarabini
    Marie-Caroline Meyohas
    Karine Lacombe
    [J]. BMC Infectious Diseases, 23
  • [43] Effects of switching to dolutegravir/lamivudine from tenofovir alafenamide fumarate/emtricitabine/dolutegravir or abacavir/lamivudine/dolutegravir on body weight and lipid profile in Japanese people living with HIV
    Ikegaya, Kenichi
    Muramatsu, Takashi
    Sekiya, Ryoko
    Sekine, Yusuke
    Harada, Yuko
    Miyashita, Ryui
    Yamaguchi, Tomoko
    Ichiki, Akito
    Chikasawa, Yushi
    Bingo, Masato
    Yotsumoto, Mihoko
    Hagiwara, Takeshi
    Amano, Kagehiro
    Takeuchi, Hironori
    Kinai, Ei
    [J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2025, 31 (02)
  • [44] Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamide/simvastatin interactionRhabdomyolysis and related complications: case report
    [J]. Reactions Weekly, 2019, 1748 (1) : 145 - 145
  • [45] Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamide/simvastatinMyopathy following drug interaction: case report
    [J]. Reactions Weekly, 2023, 1963 (1) : 175 - 175
  • [46] Reports of viral hepatitis B and C in HIV patients participating in clinical trials of elvitegravir/cobicistat/tenofovir DF/emtricitabine and cobicistat-boosted atazanavir plus tenofovir DF/emtricitabine
    Quirk, E.
    Graham, H.
    Liu, C.
    Rhee, M.
    Piontkowsky, D.
    Szwarcberg, J.
    [J]. ANTIVIRAL THERAPY, 2013, 18 : A63 - A63
  • [47] Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen
    Rizzardini, Giuliano
    Gori, Andrea
    Miralles, Celia
    Olalla, Julian
    Molina, Jean-Michel
    Raffi, Francois
    Kumar, Princy
    Antinori, Andrea
    Ramgopal, Moti
    Stellbrink, Hans-Jurgen
    Das, Moupali
    Chu, Hoa
    Ram, Renee
    Garner, Will
    Shao, Yongwu
    Chuck, Susan K.
    Piontkowsky, David
    Haubrich, Richard H.
    [J]. AIDS, 2019, 33 (10) : 1583 - 1593
  • [48] Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamideUnmasking of lues maligna with ocular involvement: case report
    [J]. Reactions Weekly, 2018, 1709 (1) : 66 - 66
  • [49] Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat/fluticasone propionate interactionAdrenal suppression: case report
    [J]. Reactions Weekly, 2015, 1553 (1) : 127 - 127
  • [50] Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide
    Orkin, Chloe
    Antinori, Andrea
    Rockstroh, Juergen
    Guillen, Santiago Moreno
    Martorell, Claudia
    Molina, Jean-Michel
    Lazzarin, Adriano
    Maggiolo, Franco
    Yazdanpanah, Yazdan
    Andreatta, Kristen
    Huang, Hailin
    Hindman, Jason
    Martin, Hal
    Baeten, Jared
    Pozniak, Anton
    [J]. HIV MEDICINE, 2023, 24 : 21 - 22
12345